Going beyond the ordinary to the extraordinary
Hinge Bio’s GEM-DIMER™ platform is creating a revolutionary class of therapeutics
Multivalent, multispecific antibody-based molecules that project freely into multidimensional space and cooperatively bind their disease target(s), enabling entirely new functionality for superior safety and efficacy.
Hinge Bio’s technology is broadly applicable across the many different therapeutic areas amenable to biologics. Hinge Bio’s novel platform has yielded product candidates for that address the problems of inadequate efficacy and resistance in the fields of infectious disease and cancer.
Hinge Bio’s lead infectious disease candidate, COVICEPT™, represents an entirely new approach to the treatment of COVID-19 by using Hinge Bio’s revolutionary technology to enhance the broad therapeutic activity of the ACE2 receptor with multivalent spike binding interactions. COVICEPT demonstrates extraordinary SARS-CoV-2 intra-spike cooperative binding and potently neutralizes viral variants better than eight clinically authorized antibodies. Hinge Bio expects its unique GEM-DIMER approach to be broadly applicable to other infectious diseases.
Hinge Bio is applying a similar approach in designing cancer therapeutics with enhanced functionality compared to existing product candidates. To date, existing antibody technologies are typically limited in the number and types of domains that can be mobilized against cancer. The multivalent, multispecific, multiplanar approach Hinge Bio is taking incorporates antibody and other protein domains that direct tumor targeting, T and NK effector cell engagement, and effector cell activation, as well as domains which are expected to localize activity to the tumor microenvironment.
Hinge Bio’s platform is protected by numerous issued patents and patent applications with broad claims covering novel compositions of matter and methods for their synthesis and use.